Cardiovascular Systems Stock

Cardiovascular Systems ROA

Delisted

The Return on Assets (ROA) of Cardiovascular Systems (CSII) as of Aug 26, 2026 is -11.45 %. In the previous year, Return on Assets (ROA) was -3.81 % — a change of 200.68% (lower).

ROA

-11.45 %

YoY

200.68%

Last updated:

In 2026, Cardiovascular Systems's return on assets (ROA) was -11.45 %, a 200.68% increase from the -3.81 % ROA in the previous year.

The Cardiovascular Systems ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2015
-19.27 USD
Jan 1, 2016
-39.34 USD
Jan 1, 2017
-0.92 USD
Jan 1, 2018
0.84 USD
Jan 1, 2019
-0.12 USD
Jan 1, 2020
-8.02 USD
Jan 1, 2021
-3.81 USD
Jan 1, 2022
-11.45 USD
The Cardiovascular Systems ROA history
YEARROAYoY
-11.45 %+200.68%
-3.81 %-52.55%
-8.02 %+6,776.12%
-0.12 %-113.86%
0.84 %-191.11%
-0.92 %-97.65%
-39.34 %+104.21%
-19.27 %-0.87%
-19.43 %
Access this data via the Eulerpool API

Cardiovascular Systems Stock analysis

What does Cardiovascular Systems do? Cardiovascular Systems Inc. (CSI) is a US medical technology company founded in 1989. The company is headquartered in St. Paul, Minnesota and employs approximately 1,000 employees worldwide. CSI develops, manufactures, and distributes innovative devices for the treatment of vascular diseases. The business model of CSI is based on the development and marketing of medical devices for minimally invasive treatment of vascular diseases. The company generates a significant portion of its revenues through the sale of its products to hospitals and specialized healthcare facilities. Additionally, CSI also offers training and educational programs for doctors and medical personnel to optimize the use of their devices. CSI operates in two main segments: peripheral arterial disease (PAD) and coronary heart disease (CHD). The PAD segment includes devices for the treatment of vascular diseases outside of the heart, such as peripheral arterial occlusive disease (PAOD). This includes the Diamondback-360® catheter and the Stealth 360® catheter, both used for plaque ablation in the arteries. The CHD segment focuses on the treatment of heart diseases such as coronary artery disease (CAD). This includes the Orbital Atherectomy System (OAS), a device that can reduce the use of stents in patients with more severe coronary artery narrowings. CSI's core product is the Diamondback-360® catheter, which was approved by the US Food and Drug Administration (FDA) in 2013. This device consists of a rotating catheter inserted into the artery to remove plaque causing vessel narrowing. The Diamondback-360 catheter is used for the treatment of PAD and has the potential to significantly improve patients' quality of life. Another important product from CSI is the Orbital Atherectomy System (OAS), used for the treatment of CAD. The OAS system is a rotating catheter that can remove plaque in the coronary arteries to improve blood flow. The use of OAS can potentially avoid costly and invasive procedures such as coronary angiography or bypass. In summary, Cardiovascular Systems Inc. is a leading company in the development and production of innovative devices for minimally invasive treatment of vascular diseases. The company specializes in two main segments, peripheral arterial disease and coronary heart disease. With products like the Diamondback-360 catheter and the Orbital Atherectomy System, CSI has established itself as a reliable provider of high-quality medical devices. Through training and educational programs, CSI also contributes to improving medical care and the development of treatment methods. Cardiovascular Systems is one of the most popular companies on Eulerpool.

ROA Details

Understanding Cardiovascular Systems's Return on Assets (ROA)

Cardiovascular Systems's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Cardiovascular Systems's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Cardiovascular Systems's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Cardiovascular Systems’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Cardiovascular Systems stock

Return on Assets (ROA) of Cardiovascular Systems is -11.45 % in 2026.

Return on Assets (ROA) of Cardiovascular Systems changed from -3.81 % to -11.45 %, representing a 200.68% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Cardiovascular Systems since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Cardiovascular Systems with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

Profitability — Cardiovascular Systems

All Key Metrics — Cardiovascular Systems